TP53 and myelodysplastic syndrome: The mutant p53-targeting compound APR-246 is currently being tested in phase III clinical trials in patients with TP53 mutant MDS and several phase I and II studies in other hematological malignancies with mutant TP53 or solid cancers independent of TP53 status.